Drug Topics

JANUARY 3, 2025

Researchers explored ideas of simplifying the vaccination process to yield higher rates of adult immunization, similar to that of the COVID-19 pandemic.

Vaccines 185

Vaccines Immunization 185

Pharmacy Times

JANUARY 2, 2025

Over 70% of children and young people with long COVID reported improvements in their symptoms within 24 months of their initial positive SARS-CoV-2 test.

145

145

Drug Topics

DECEMBER 31, 2024

Check out this list of our top 5 most read obesity stories from the year 2024.

187

187

Fierce Healthcare

JANUARY 2, 2025

In this month's payer roundup, CVS faces antitrust questions from Congress as the company lays off more workers following a failed Medicaid bid in Kansas, Oscar Health CEO Mark Bertolini has a bold idea to remake health insurance and Johnson & Johnson is suing Express Scripts in a long-running lawsuit.

Insurance 141

Insurance 141

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

PharmaVoice

JANUARY 2, 2025

A handful of innovative startups are scrambling to gain a foothold as technology improves at a rapid clip.

126

126

STAT

DECEMBER 30, 2024

Although bipartisan legislation to provide Medicare coverage for obesity treatments has circulated in Congress for more than a decade, the Congressional Budget Office (CBO) ventured to  estimate  the budgetary effects of such a policy for older Americans starting in 2026 for the very first time in a report published in October.  The CBO should be commended for conducting this comprehensive analysis.

125

125

Fierce Healthcare

JANUARY 2, 2025

The group is concerned about understaffing, retention challenges and low pay. NYC H+H affiliates and the Doctors Council have been negotiating a new contract for 15 months.

115

115

The Checkup by Singlecare

JANUARY 2, 2025

As glucagon-like peptide-1 (GLP-1) receptor agonists continue to surge in popularity, the U.S. Food and Drug Administration approved the second generic in this class of medications: liraglutide (Victoza). This approval follows the generic version of Byetta (another GLP-1) in November. Generic liraglutide is the first once-daily generic GLP-1 injectable approved to treat Type 2 diabetes in patients 10 and older, alongside diet and exercise.

FDA 105

FDA Insurance Coverage Insurance 105

STAT

DECEMBER 30, 2024

Work by device manufacturers to improve the performance of pulse oximeters on people with darker skin has progressed little since the Food and Drug Administration asked manufacturers in 2013 to voluntarily test the devices on more diverse skin tones, according to a study published Monday in JAMA. The study and a related editorial suggest clearer guidance, enforcement, and possibly legal action may be necessary to ensure the devices work well on all skin tones.

Documentation 131

Documentation FDA 131

Drug Topics

JANUARY 6, 2025

A study found that of 110 patients with long COVID, over half reported decreased QOL due to pain, discomfort, anxiety, or depression.

123

123

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

DECEMBER 31, 2024

The potential treatments include ivermectin, methylene blue, glucagon-like peptide-1 receptor agonists, and low-dose naltrexone.

139

139

pharmaphorum

JANUARY 3, 2025

CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satri-cel has shown efficacy in gastric cancer, setting up a filing in China.

105

105

The Checkup by Singlecare

DECEMBER 30, 2024

Sold under brand names such as Amvaz, Katerzia, Norliqva, and Norvasc , amlodipine is a medication that is FDA approved for the treatment of hypertension (high blood pressure), chronic stable angina (chest pain and pressure), vasospastic angina (coronary artery spasm), and coronary artery disease. It belongs to a class of medications called calcium channel blockers, which is further broken down into two classes: dihydropyridine calcium channel blockers and nondihydropyridine calcium channel bloc

Hospitals 98

Hospitals FDA 98

Med Ed 101

JANUARY 1, 2025

I’ve compiled this YouTube video to help candidates best prepare for their 2025 BCPS pharmacy exam. Pass rates continue to be in the 60% range so it is difficult to pass this exam. There are significant changes this year in the 2025 BCPS Exam compared to last spring. The content outline has shifted significantly. Here […] The post 2025 BCPS Pharmacy Exam – What You Need To Know appeared first on Med Ed 101.

105

105

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Drug Topics

JANUARY 6, 2025

US News & World Report nutrition experts detailed the best types of diets for maintaining patient health in 2025.

98

98

Pharmacy Times

JANUARY 1, 2025

Lp(a) is a critical risk factor for atherosclerotic cardiovascular disease, but current lipid-lowering therapies are largely ineffective at lowering Lp(a) levels.

139

139

pharmaphorum

JANUARY 3, 2025

Capricor completes its US filing for deramiocel, vying to become the first FDA-approved therapy for cardiomyopathy in Duchenne muscular dystrophy.

FDA 105

FDA 105

STAT

DECEMBER 30, 2024

Axsome Therapeutics is moving ahead with plans to submit its Alzheimer’s disease treatment for Food and Drug Administration approval despite mixed results from two new clinical trial readouts.  Axsome, which is based in New York, announced Monday that its drug AXS-05 met the primary endpoint of one trial testing the therapy for agitation caused by Alzheimer’s, but failed to show statistical significance in another.

FDA 110

FDA 110

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

The Checkup by Singlecare

JANUARY 3, 2025

Contrave is a brand-name medication approved by the U.S. Food and Drug Administration (FDA) for chronic (long-term) weight management in certain adults. It should be taken with a reduced-calorie diet and increased physical activity. As a combination drug that contains an opioid antagonist and antidepressant, it affects the brain to make you feel fuller and lower your appetite.

FDA 88

FDA 88

Drug Topics

JANUARY 6, 2025

Using the DASH Rapid PCR System, providers can yield test results in under 1 minute of hands-on time.

FDA 98

FDA 98

Pharmacy Times

DECEMBER 31, 2024

Bispecific antibodies amivantamab and tarlatamab hold promise for patients.

132

132

pharmaphorum

JANUARY 2, 2025

Early cancer diagnoses have risen to record levels in England, says NHS, but long waiting times for treatment threaten to undermine the gains.

105

105

Fierce Healthcare

JANUARY 2, 2025

HHS is backing away from a proposed rule that would've worked around an employer's religious objections to contraceptive coverage without cost sharing.

101

101

STAT

JANUARY 6, 2025

Five years ago this week, STAT was interviewing nervous infectious disease scientists about a mysterious disease spreading in the central Chinese city of Wuhan, located roughly 500 miles west of Shanghai. On Jan. 4, 2020 , we published the first of what would become a torrent of articles on the disease now known as Covid-19.  The intervening years have both sped and crawled by, too busy at times to take stock of all that has changed, too plodding to believe we ha

93

93

Drug Topics

JANUARY 6, 2025

PQA Health Equity Technical Expert Panel recommendations inform measure testing, use in quality programs, and risk adjustment models

98

98

Pharmacy Times

JANUARY 1, 2025

Administering first-dose antibiotics to septic shock patients via IV push rather than continuous infusion could improve the speed of antibiotic delivery and reduce logistical challenges.

130

130

pharmaphorum

DECEMBER 31, 2024

Sangamo is 'surprised and disappointed' by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results

105

105

Fierce Healthcare

JANUARY 3, 2025

Mimicking prior federal and state investigations into drug manufacturers, health insurer Aetna is suing in Connecticut for rigging the generic drug market.

Insurance 98

Insurance 98

The Checkup by Singlecare

DECEMBER 31, 2024

Adderall ( amphetamine-dextroamphetamine ) and Vyvanse ( lisdexamfetamine dimesylate ) are brand-name ADHD medications. They belong to a class of drugs called central nervous system stimulants ( CNS stimulants ). Some people with attention deficit hyperactivity disorder ( ADHD ) or their caregivers might have heard that there are benefits to taking both Vyvanse and Adderall.

FDA 96

FDA Dosage Controlled Substances Insurance 96

Drug Topics

JANUARY 3, 2025

A study found that sending a letter to providers about standards of care and glucagon preparations could increase glucagon prescription rates.

98

98

Pharmacy Times

JANUARY 1, 2025

Some outsourcers and pharmacies have capitalized on the shortages, producing compounded versions.

Compounding 128

Compounding FDA 128

pharmaphorum

DECEMBER 30, 2024

BMS beats MSD to the US subcutaneous PD-1 inhibitor market after Opdivo Qvantiq is cleared across nearly all the indications of the IV form

103

103

The Guardian - Pharmaceutical Industry

JANUARY 4, 2025

Danish drug company gave money for Google ads to promote weight loss services and received data on web traffic and prescriptions The Danish drug company Novo Nordisk provided hundreds of thousands of pounds worth of sponsorship to pharmacies including Boots and Lloyds as it sought to boost sales of its slimming drugs in Britain, the Observer can reveal.

82

82